微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 47.2% | -5.45% | 5.53% | 75/159 | 31.52% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 44.72% | 2.58% | -3.69% | 91/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 46.43% | 0.99% | -0.75% | 85/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 46.79% | 5.87% | -6.26% | 85/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 49.91% | 13.95% | 14.49% | 78/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 43.6% | 37.62% | -5.18% | 98/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 45.98% | 57.43% | 4.04% | 91/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 44.19% | 67.53% | 0.89% | 96/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 43.8% | 65.72% | 38.28% | 95/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 31.68% | -17.08% | 8.46% | 120/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 29.21% | -33.14% | 10.71% | 119/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 26.38% | -38.44% | -0.2% | 130/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 26.43% | -37.78% | -30.81% | 124/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 38.2% | -0.92% | -12.54% | 110/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 43.68% | 15.14% | 1.94% | 84/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 42.85% | 21.64% | 0.87% | 91/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 42.48% | 17.88% | 10.18% | 81/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 38.56% | 8.97% | 1.64% | 110/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 37.94% | 7.37% | 7.68% | 94/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 35.23% | -0.71% | -2.24% | 109/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 36.04% | -0.22% | 1.85% | 90/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 35.39% | -5.43% | 0.14% | 110/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 35.34% | -2.1% | -0.42% | 89/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 35.48% | 0.89% | -1.75% | 91/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 36.12% | -16.51% | -3.47% | 84/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 37.42% | -9.21% | 3.67% | 100/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 36.09% | -5.54% | 2.62% | 81/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 35.17% | -7.74% | -18.7% | 83/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 43.26% | 16.56% | 4.96% | 66/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 41.22% | 4.8% | 7.87% | 78/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 38.21% | 0.23% | 0.23% | 65/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 38.12% | 5.07% | 2.71% | 69/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 37.12% | 6.43% | -5.63% | 59/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 39.33% | -15.63% | 3.17% | 71/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 38.12% | -21.13% | 5.07% | 48/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 36.28% | -21.73% | 4.04% | 58/159 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 34.87% | -19.03% | -25.19% | 52/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 46.61% | -27.11% | -3.56% | 46/159 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 48.34% | -24.5% | 4.27% | 31/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 46.35% | -25.89% | 7.62% | 38/159 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 43.07% | -30.75% | -32.65% | 37/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |